For years, alternative medicine has proven to be a controversial topic, to say the least. For so long, the western world especially has taken the view that alternative medicines are decidedly dangerous for use. The result has been that many of these alternative medicines - including CBD (or, cannabidiol) - have been categorised in the same group as illicit substances like cocaine, ecstasy, ice, and heroin. It is not fair, however that is the fact of the matter. While Chinese medicine has long embraced the advantages, benefits, and powers of alternative medicine, the western world has always lagged behind.
Until now, that is. A growing pool of research and studies over the years - and especially in recent years - has led to the readjustment of the legal status of alternative medicines like CBD. This is still very much a work in progress, however it is a work in progress that is making greater and more positive strides all the time. This is just the start and the best is yet to come. That is a point that is worth celebrating and encouraging forward. Even so, it is important to understand the journey up until this point so as to better understand the journey forward and beyond.
The shift in attitude towards alternative medicines
Recently - and especially over the last twelve months or so - we have seen a tremendous amount of growth and overall acceptance for the fact that alternative medicines are not as bad for us (if they are bad at all, which, spoiler alert, most of them truly are not) as we have been led to believe for quite some time. The growing pool of research and studies caters to the fact that we are finally experiencing and seeing a shift in attitude towards alternative medicines that is opening the gateway for a healthier and more positive future for medicine altogether.
Alternative medicine businesses getting more funding
We are finally seeing alternative medicine businesses get the funding that they have always deserved. CBD oil is just one example of the tremendous power of research and studies. In recent years especially, there has been a growing pool of research and studies that have all proven to be a testament to the fact that CBD is a positively powerful natural treatment for many aches and pains that the body and even the mind can go through. In fact, the CBD market is expected to reach a global value of $20 billion by the year 2024. That is a massive prospective growth and it speaks volumes of the power and promise in alternative medicine.
What this means for the future and beyond
Heading into the future and beyond, we are going to keep seeing alternative medicine businesses continue to take their place on centre stage, getting the funding and recognition that they have always deserved. This is just the start, however it is a start that is gaining more and more momentum all the time. The era of alternative medicine is just now getting started. The best is yet to come and that is a point to celebrate and encourage onward and upward.
This article does not necessarily reflect the opinions of the editors or management of EconoTimes


California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 



